OBI Pharma Announces Completion of Patient Enrollment in Phase 2/Phase 3 Clinical Trial of OBI-822 Active Immunotherapy for Metastatic Breast Cancer

OBI Pharma, Inc. won Taiwan “Venture Capital Star” The Best Investment Award

OBI Pharma Announces NT$ 1.5 Billion Capital Infusion

OBI Pharma Wins the "Greatest Potential Award" at the 2013 Outstanding Biotech Awards

OBI Pharma re-elects its board of directors and supervisors, and selects a new chairman of the board.

OBI Pharma to launch Phase 1 clinical trial for a new generation of carbohydrate cancer immunotherapy in 2014.

OBI's company English name official renamed OBI Pharma, Inc.

Breast Cancer New Drug: OBI-822/821 received Taiwan FDA Approval for entering Phase III trial

DIFICID (Fidaxomicin) Approved by Taiwan Department of Health for the Treatment of CDAD